USPTO serial 79266404
EHP
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 2, 2021
- Examiner
- FALK, JONATHAN ROBERT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with EHP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Margaret C. McHugh
Margaret C. McHugh KILPATRICK TOWNSEND & STOCKTON LLPTWO EMBARCADERO CENTER SUITE 1900SAN FRANCISCO, CA 94111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical apparatus for treating tumors of the human or animal body; apparatus for purifying the blood during surgical or therapeutic procedures; medical apparatus and instruments, namely, blood, blood purification, toxin, pesticide, parasite, drug, poison, heavy metal, bacteria and virus, immunopathogenic agent, bilirubin, and beta 2 microglobulin filters; medical apparatus and instruments, namely, drug delivery, blood, fluid, peristatic, membrane, and centrifugal pumps; medical apparatus and instruments, namely, adsorbers for blood purification and removal of toxins, pesticides, parasites, drugs, poison, heavy metal, bacteria, viruses, immunopathogenic agent, bilirubin, beta 2 microglobulin from the blood; medical apparatus and instruments, namely, heat exchangers, oxygenators, devices for ozone production, ozone devices for treatment of blood, ozone devices for the killing and removal of bacteria, viruses, and parasites, tube systems comprised of tubes for passing blood and fluids, hemoperfusion devices, blood purification devices, devices for inducing hyperthermia, devices for thermotherapy, blood perfusion devices, perfusion devices for the treatment of blood, perfusion cutlery for surgery; surgical apparatus and instruments; diagnostic and therapeutic equipment in the pharmaceutical, medical and veterinary fields, namely, equipment for blood gas analysis, devices for measuring blood coagulation, devices for measuring oxygen saturation, devices for measuring body temperature, hemoperfusion devices for the treatment of blood, clinical laboratory analyzers for blood and blood component analysis, chemistry analyzers for blood and blood component analysis, automated sample handling equipment for testing purposes, immunohematology analyzer for blood and blood component analysis, apparatus for blood screening, blood typing, detection of assays associated with blood screening and blood typing used in the transfusion medicine market; medical instruments for the extracorporeal destruction of cancer cells, namely, heat exchangers, devices for inducing hyperthermia, devices for thermotherapy; medical instruments for the extracorporeal purification of the blood and supply of natural or chemical substances to the body, namely, filter, pumps, adsorbers, infusion equipment for drug delivery, pain therapy, blood purification, blood perfusion; medical instruments, namely, patient cradle equipment suitable for use in hyperthermia, thermotherapy or thermometry treatments, namely, control devices, control systems, controller such as temperature controller; medical apparatus, equipment and instruments for chemotherapy and electrochemical tumor therapy; medical apparatus, namely, hyperthermia systems, namely, heat exchangers, devices for inducing hyperthermia, devices for thermotherapy | ACTIVE | — |
| 042 | Advisory or additive services relating to therapy for the treatment of tumors of the human or animal body, namely development of medical imaging methods, laboratory analyses, chemosensitivity testing, gene analyses for medical research or diagnostic purposes; advisory or additive services relating to therapy for the purification of blood in surgical or theoretic procedures, namely imaging methods, laboratory analyses, medical laboratory chemosensitivity testing, gene analyses for medical research purposes, therapy monitoring for medical research purposes, therapy setting for medical research purposes, therapy adjustment for medical research purposes; services provided by a supplier of medical apparatus and instruments, namely technical advice relating to the operation of medical equipment and instruments adapted to the customer's specific applications, functional analysis, device adjustment in the nature of calibration, quality control, calibration of medical equipment and instruments; development and research services relating to new products for third parties in the field of hemoperfusion therapy or hyperthermia, therapy based on hyperthermia, oxygen supply and adsorption of molecules from blood; biological research; research in the field of chemistry; research in the field of hemoperfusion therapy or hyperthermia, therapy based on hyperthermia, oxygen supply and adsorption of molecules from blood | ACTIVE | — |
| 044 | Medical services in the field of oncology; medical services for the treatment of diseases of the human or animal body; provision of heat therapy for treating tumors in human or animals, hyperthermia, hemoperfusion therapy; blood purification services for surgical or therapeutic procedures | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Dr. med. Gerhard Siebenhüner
- Other trademarks owned by Dr. med. Gerhard Siebenhüner
- Other trademarks owned by Dr. med. Gerhard Siebenhüner
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EHP
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 2, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 30, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 6, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 6, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 2, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 2, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 12, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 26, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 17, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 17, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 28, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 28, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 9, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 9, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 9, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 9, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 6, 2020 | RDX3 | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED | — |
| Aug 6, 2020 | RDX1 | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED | — |
| Aug 6, 2020 | RRDX | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED | — |
| Jul 8, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 7, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 7, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 14, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 14, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 14, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 20, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 19, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 19, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 26, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 26, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 14, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 13, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 10, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |